Immune checkpoint inhibitor use in antisynthetase syndrome

• Published in: Asia-Pacific journal of clinical oncology 2019, Vol.15 (4), p.266-269
• Main Authors: Mackintosh, David, Islam, Mohammed F, Ng, Jennifer, Basham, Jane
• Format: Report
• Language: English
• ISSN: 1743-7563
• DOI: 10.1111/ajco.13141

We report on the unique case of a patient with antisynthetase syndrome and metastatic non-small cell lung cancer undergoing therapy with the PD-1 checkpoint inhibitor, nivolumab. Despite adequate autoimmune disease control over a period of 12 months, the patient rapidly experienced a flare of interstitial lung disease following initial nivolumab administration, which ultimately proved fatal. The use of immune checkpoint inhibitors in patients with autoimmune disease is becoming more commonplace, however this is the first reported case of the use of these agents in a patient with antisynthetase syndrome. Additionally, the patient's initial clinical presentation with antisynthetase syndrome and simultaneous primary lung cancer, a rare association of which there are few case reports, makes this case interesting and unusual.